Frontline Healthcare Partners has announced a recapitalization and growth investment in LivWell Infusions.

LivWell, based out of Scottsdale, Ariz., is a provider of outpatient infusion therapy, with services offered through ambulatory infusions centers and infusions practice management. Founded in 2020, the company currently provides infusion services to patients across allergy/immunology, cardiology, gastroenterology, oncology, ophthalmology, neurology…

On July 15, the U.S. Department of Labor proposed a new regulation that would require successor government contractors to offer employees of predecessor contractors the first right of refusal for employment on certain contracts.

Read on for more information about the proposed regulation.

Arsenal Capital Partners has announced that it has completed fundraising for two new funds, totaling $5.4 billion in capital commitments.

Arsenal Capital Partners VI (Fund VI) closed with $4.3 billion in capital commitments. This exceeded its $3.0 billion target. The firm said Fund VI will focus on investments in healthcare and industrials businesses with proven technologies and solutions.

Arsenal Capital Partners…

Securities and Exchange Commission v. Alexandra Robert et al. was filed in the United States District Court for the Southern District of Florida on July 26, 2022, claiming violations of several provisions of the Securities Act and Securities Exchange Act. Specifically, the SEC seeks permanent injunctive relief against all Defendants in order to prevent future violations of the federal securities laws, disgorgement of any ill-gotten gains, and civil damages.

The SEC brought this action against Defendants Alexandra Robert (“Robert”), the owner, founder, and CEO of Defendants Chalala Academy LLC (“Chalala”), a Florida limited liability company, and Lendvesting Academy Corp. (“Lendvesting”), a Florida-registered corporation formerly operating as a d/b/a of Chalala.

The complaint alleges from at least May 2020 through August 2021, Defendants fraudulently raised approximately $900,000 from roughly 80 investors, mostly Haitian and Haitian-Americans living in South Florida, by offering unregistered “investment programs” falsely promising guaranteed returns of up to 48%. Defendants falsely told investors that they would make interest generating loans to small businesses that would otherwise not qualify for traditional financing, thereby providing investors with high fixed returns.

SFW Capital Partners has announced it has completed a strategic investment in Sannova Analytical.

Sannova, founded in 2006 and based in Somerset, N.J., is a contract research organization providing bioanalytical and chemistry manufacturing and controls testing services to pharmaceutical and biotech companies.

SFW, based in Rye, N.Y., is a private equity firm focused…

McGuireWoods’ Ponzi Litigation team launched its Ponzi Perspectives blog in early 2021.  Since that time, our focus is to track key cases and decisions that have the potential to influence controlling law on Ponzi-related issues.  The blog also offers analysis on practical considerations when defending Ponzi litigation.  This 2022 mid-year round up summarizes the new…

BPOC has announced a strategic investment in Praxis Packaging Solutions.

Praxis, founded in 1989 and based in Grand Rapids, Mich., is a provider of primary and secondary contract packaging services for over-the-counter and prescription pharmaceutical, medical device, animal health and health and beauty industries.

BPOC, based in Chicago, seeks control and minority equity…

On July 20th, on the eve of trial, Biogen Inc. agreed to pay $900 million dollars to settle claims that the company violated the False Claims Act (FCA) by allegedly paying improper consulting and speaker fees and providing lavish meals and entertainment (in violation of the Federal Anti-Kickback Statute (AKS)) to medical providers to induce them to prescribe its multiple sclerosis drugs Avonex, Tysabri, and Tecfidera.  The qui tam (or whistleblower) suit was filed in the District of Massachusetts in 2012 by former Biogen employee Michael Bawduniak and merged with multiple suits with similar allegations. The settlement is extraordinary in size, particularly in light of the United States’ decision declining to intervene in the suit, and highlights the risks associated with pharmaceutical and device manufacturers hiring providers as consultants and conducting speaker programs.

On July 20, Biogen Inc. agreed to pay $900 million to settle claims the company violated the False Claims Act by allegedly paying improper consulting and speaker fees and providing lavish meals and entertainment to medical providers to induce them to prescribe the multiple sclerosis drugs it manufactures.

Read on for details about this unusually…